Prof. Philippe Eckert
General Director
Welcome to the Lausanne University Hospital, better known in French as CHUV!
Located in the heart of the Lake Geneva "Health Valley", CHUV is one of Switzerland's five university hospitals and one of the fifteen best in the world, according to a 2020 classification by Newsweek magazine.
Our public service hospital plays a leading role in the fields of medical care, research and training, thanks to its collaboration with the Faculty of Biology and Medicine at the University of Lausanne (UNIL).
With a vision of medicine at the crossroads of the sciences and humanities, CHUV also has numerous links within Switzerland and abroad.
I hope that the pages of this website, as well as the In Vivo selection of projects below, will help you to gauge the pulse of our hospital: every project makes its own contribution towards the “thinking health” of the future.
Welcome again!
Key numbers
Explore our hospital’s 2019 profile via a few key figures.
1,7
billion (annual budget in Swiss francs)
0
patients hospitalised
0
employees
0
nationalities
Coordinating the Swiss arm of “Solidarity”
Supported by the Swiss National Science Foundation (NSF) and in collaboration with the Federal Office of Public Health (FOPH), CHUV is coordinating Switzerland’s participation in the “Solidarity” study.
Read more
Understanding the impact of COVID-19 on pregnancy
CHUV has created the “International COVID-19 and Pregnancy Registry” (COVI-Preg), which aims to assess the impact of SARS-CoV 2 on pregnancy and the health of mothers and newborns.
Read more
Providing better support for people during a pandemic
The “Collaborative Outcomes Study on Health and Functioning during Infection Times” (COH-FIT), which involves almost 200 researchers from over 40 countries on six continents, aims to measure the impact of the COVID-19 on physical and mental health.
Read more
Predicting the severity of the illness using immune signatures
The research project “Defining the immune signatures in SARS-CoV-2 infected individuals in blood and tissues” aims to identity the biological markers that predict the severity of the illness.
Read more
Host determinants of severe COVID-19, learning from extreme cases
Supported by the SNF, this research project is based on the hypotheses that severe presentation of COVID-19 results from genetic predisposition and that transcriptomic profiling at an early stage may help predict adverse outcomes.
Read more
Identifying antibodies that can neutralise the coronavirus
As part of the “Corona Accelerated R&D in Europe” (CARE) programme, the Allergy and Immunology Department at CHUV has secured funding of almost 5 million Swiss francs for its work aimed at isolating antibodies that neutralise the coronavirus.
Read more
Developing the leading blood test for Switzerland
In conjunction with the École polytechnique fédérale de Lausanne (EPFL) and the Swiss Vaccine Research Institute (SVRI), CHUV has developed the blood test selected for conducting population studies in Switzerland.
Read more
Tackling cancer treatment resistance with FLASH
FLASH radiotherapy is a new form of treatment pioneered by the CHUV Service of radiation oncology.
Read more
Walking again
High hopes are being raised by the STIMO project, which has enabled some paralysed persons to regain the use of their legs.
Read moreSee all projects
Think health
The multi award-winning In Vivo magazine published by CHUV and produced in conjunction with the LargeNetwork agency offers an overview of medical innovation in French-speaking Switzerland and throughout the world. With the "Think health" editorial line, it first tackles the issues of health policies and the ethical aspects of modern medical practice. The magazine has a print run of 17,500 copies, is translated into English for the digital version, and features an infographic supplement called In Extenso.
